Clinical trials: Geriatric Hematology
Asthma
A Study of Depemokimab in Participants of 6 to 11 Years of Age
This study is aimed at assessing depemokimab as an add-on medicine for the treatment of asthma with type-2 inflammation in participants of 6 to 11 years of age.
- Trial name
- GLIDE (NCT07671001)
- Testing
- Depemokimab
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Anemia
Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects
Safety, tolerability, pharmacokinetics and pharmacodynamics will be investigated in a single dose group stratified study in renal impaired and healthy subjects.
- Trial name
- NCT01318551
- Testing
- BAY85-3934
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bayer
Leukemia
Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia
RATIONALE: Classical chemotherapy does not cure advanced chronic lymphocytic leukemia (CLL) despite new drugs. Rituximab is a monoclonal antibody directed against CD20 surface antigen on B lymphocytes and leads to apoptosis of…
- Trial name
- LLC2007SA (NCT00645606)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 542 people
- Sponsor
- University Hospital, Tours
Transfusion-dependent Anemia, Surgery
Liberal Transfusion Strategy in Elderly Patients
In this prospective, multicentre, open, randomised, controlled clinical trial elderly patients (≥ 70 years) undergoing intermediate- or high-risk non-cardiac surgery will be randomised either to a liberal group (patients receive…
- Conditions
- Transfusion-dependent Anemia, Surgery, Anemia
- Trial name
- LIBERAL (NCT03369210)
- Testing
- red blood cell transfusion trigger
- Where
- 17 sites in Germany
- Volunteers
- 4,456 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Chronic Lymphocytic Leukemia
Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia
The purpose of this study is to determine if Ruxolitinib, an inhibitor of cytokine-signaling, is effective in the treatment of patients with Chronic Lymphocytic Leukemia for whom conventional chemotherapy is either too toxic or…
- Trial name
- NCT02015208
- Testing
- Ruxolitinib
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- Sunnybrook Health Sciences Centre
Acute Myeloid Leukemia
Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients
These study is designed to evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin in elderly AML.
- Trial name
- LAM-RAPA (NCT00235560)
- Testing
- rapamycin
- Where
- 3 sites in France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Toulouse
Anemia
The Prevalence of Malaysian Children Aged ≥ 6 to ≤ 36 Months at Risk of Anaemia
The main purpose of this study is to determine the prevalence of Malaysian children aged ≥ 6 to ≤ 36 months at risk of anaemia by measuring Total Haemoglobin (SpHb) using a non-invasive haemoglobin assessment.
- Trial name
- NCT05181436
- Testing
- measuring Total Haemoglobin (SpHb) using Masimo Rad-67.
- Where
- Malaysia
- Volunteers
- 1,215 people, healthy volunteers welcome
- Sponsor
- Danone Specialized Nutrition (M) Sdn Bhd
Acute Myeloid Leukemia
Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia
This is a Phase I, open-label, non-randomized, multicenter study to evaluate the safety, pharmacokinetics and preliminary efficacy of HMPL-523 in combination with Azacitidine in previously untreated elderly patients with AML who…
- Trial name
- NCT03483948
- Testing
- HMPL-523, Azacitidine
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Hutchison Medipharma Limited
Multiple Myeloma
Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone
Recent prospective multicenter phase II study assessed the efficacy and tolerability of lower dose lenalidomide (15mg) and dexamethasone (20mg) in frail patients with relapsed or refractory MM.
- Trial name
- LENDER (NCT03809780)
- Testing
- Lenalidomide, Dexamethasone
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Kosin University Gospel Hospital
Leukemia
VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as VNP40101M and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00354276
- Testing
- cytarabine, laromustine
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 85 people
- Sponsor
- Vion Pharmaceuticals
Multiple Myeloma
Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma
Multiple myeloma is an incurable hematological malignancy that affects older patients. Currently, despite recent progress, the disease relapses more or less quickly after initial treatment and requires the resumption of treatment…
- Trial name
- IDARA (NCT03757221)
- Testing
- Ixazomib and Daratumumab
- Where
- France
- Volunteers
- 55 people
- Sponsor
- University Hospital, Caen
Cognitive Impairment, Haematological Malignancy
Cognitive Status Assessment In Elderly Patients With Active Treatment For Haematological Malignancies
BACKGROUND Neurocognitive symptoms have a high prevalence in cancer patients, resulting in a significant impact on daily life and tolerance to therapy.
- Conditions
- Cognitive Impairment, Haematological Malignancy, Chemo-brain
- Trial name
- NCT04673305
- Testing
- Cognitive Assessment, Cytokine dosage
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Ospedale San Carlo Borromeo
Purpura
Study to Assess DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Forearms and Hands
To determine the efficacy (measured at 12 weeks) of DerMend Moisturizing Bruise Formula in improving the appearance of bruising and reducing the appearance of photoaging of the forearms and hands in mature skin.
- Trial name
- CCCR-28-2013 (NCT01910831)
- Testing
- DerMend Moisturizing Bruise Formula
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Center for Clinical and Cosmetic Research
Leukemia
"AIDA" Protocol (LAP 0493)
The main purposes of the AIDA protocol are to test the role of intermittent maintenance therapy with ATRA, standard maintenance chemotherapy with methotrexate and 6-mercaptopurine of both in PCR negative patients at the end of…
- Trial name
- NCT01064557
- Testing
- all-trans retinoic acid (ATRA)
- Where
- 80 sites in Belgium, Germany and 3 more
- Volunteers
- 1,068 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Precursor Cell Lymphoblastic Leukemia
Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL
The trial proposed to evaluate the efficacy and safety of an inotuzumab ozogamicin followed by maintenance treatment in patients with acute lymphoblastic leukemia older than 56 years
- Trial name
- NCT03460522
- Testing
- Inotuzumab ozogamicin
- Where
- 14 sites in Germany
- Volunteers
- 65 people
- Sponsor
- Nicola Goekbuget
Neutropenia
A Study to Investigate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Children
This is a study to investigate the pharmacokinetics, safety and tolerability of several doses of voriconazole, intravenous and oral suspension formulations, in children
- Trial name
- NCT00174473
- Testing
- Voriconazole
- Volunteers
- 49 people
- Sponsor
- Pfizer
Multiple Myeloma
Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients
This study will determine whether the association of Revlimid and Prednisone (RP) as induction treatment followed by Revlimid, Melphalan and Prednisone (MPR) as consolidation treatment is safe and induce a significant rate of PR…
- Trial name
- RP_MPR (NCT01160107)
- Testing
- RP followed by MPR
- Volunteers
- 46 people
- Sponsor
- Fondazione EMN Italy Onlus
Hematologic Malignancies
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged >/= 65 years with hematologic malignancies.
- Trial name
- GeriBMT (NCT05849207)
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Ronald Paquette
Multiple Myeloma
Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients
The proposed study will evaluate whether the combination of VELCADE, Thalidomide , Melphalan and Prednisone (V-MPT), as induction treatment for newly diagnosed elderly MM patients, improves outcomes compared to the combination…
- Trial name
- NCT01063179
- Testing
- Bortezomib, Melphalan, Prednisone, Thalidomide, Bortezomib, Melphalan, Prednisone
- Where
- Italy
- Volunteers
- 511 people
- Sponsor
- Fondazione EMN Italy Onlus
Hematologic Malignancies
The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation
This trial is a prospective, single-arm, single-center clinical study. A total of 44 elderly (aged 60 to 69 years) patients with hematological malignancies who need to receive a single-unit unrelated umbilical cord blood…
- Trial name
- NCT07441967
- Testing
- Thiotepa, Fludarabine, G-CSF
- Volunteers
- 44 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China